|
| Australia | China | Europe |
| HC population | 0.24 million | 13 million | 7.6 million |
| HCV prevalence | 0.96% (for the entire population) | 1.8% - 3.7% | Approximately 1.0% |
| Main GT | 1a and 1b (54% prevalence) 3a (37% prevalence) | 63% 1b 17% 2b | 68% 1b 30% 2a |
| Treatment | DAAs | PEG-IFN/IFN + RBV DCV + ASN | DAAs |
| Access | Hospitals, specialists | Hospital | Hospitals, specialists |
| Cost/per course ($) | 38.30 for general patients 6.20 for concessional patients | PEG-IFN + RBV-4976 DCV + ASN-8560 | 7014 - 11690 |
| Income per capita ($) | 55,914 | 7442 | 28,900 |